tumor mutational burden Mar 15, 2022 Illumina Obtains CE-IVD Marking for European Version of TSO Comprehensive Assay Mar 10, 2022 Oxford BioDynamics Gathering Real-World Data on Checkpoint Inhibitor Response Predictor Premium Jan 7, 2022 Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps Dec 30, 2021 Top 10 Precision Oncology Articles in 2021: Liquid Biopsy, Difficult Reimbursement, TMB Debates Dec 20, 2021 Survey of Precision Oncology Programs Shows Rapid Pace of Advances a Major Challenge for Oncologists Oct 8, 2021 TGen Study Highlights Value of Repeat Tumor Profiling for Pediatric Solid Tumors Premium Aug 19, 2021 Mounting Research Backs MHC as Immune Checkpoint Inhibitor Biomarker Premium Jul 29, 2021 Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues Jul 9, 2021 Strata Oncology Developing Integrated TMB, PD-L1, PD-L2 Test to Predict Checkpoint Inhibitor Benefit Premium Apr 29, 2021 TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis Apr 14, 2021 Tecentriq Response Analysis in MyPathway Study Bolsters Case for Higher TMB Cutoff Premium Apr 1, 2021 Tumor-Only Sequencing for TMB Measurements May Inflate Scores in Black Patients Premium Mar 25, 2021 Oncologists Look to FDA as New Publications Poke Holes in TMB-High Keytruda Approval Premium Feb 18, 2021 MSK Study Underscores Need to Validate Cancer-Specific Tumor Mutational Burden Cutoffs Premium Jan 7, 2021 MSK Researchers Chip Away at TMB Unknowns, Clarify Role in Predicting Immunotherapy Benefit Premium Jan 5, 2021 Precision Oncology in 2020: Pandemic Lessons, Biomarker Controversies, Community Access Gaps Premium Dec 29, 2020 Top 20 Precision Oncology Articles in 2020: Pandemic, FDA Approvals, TMB, Liquid Biopsy CDx, More Nov 17, 2020 Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition Nov 9, 2020 FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza Oct 7, 2020 Immunotherapy Response Prediction Improved by Baseline, On-Treatment Biomarker Combo Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
